Chukwunonso Nwabufo on Clubhouse
Bio
Chuk is an accomplished pharmaceutical scientist with over 5 years of experience in drug development across academia and the pharmaceutical industry.
✅ Senior Research Associate, Gilead Sciences Canada (2019 - 2021)
💡Contributed to the development and approval of Remdesivir for the treatment of COVID-19
💡Contributed to the ongoing development of Lenacapavir as a long-acting antiretroviral drug for improving medication adherence for HIV patients
✅ PhD Pharmaceutical Sciences - University of Toronto, Canada (2024)
✅ Research: Improving the clinical efficacy and safety profile of COVID-19 drugs
✅ Recipient of Canadian Institutes of Health Research Doctoral Award ($105K) - Ranked Top 11.65% out of 515 national applicants
✅ Recipient of over 20 international, national, and local awards (over $200K) for research, academic, and leadership accomplishments.
✅ MBA (93%) - Quantic School of Business and Technology, USA
✅ MSc Pharmacy (90%) - University of Saskatchewan Canada
✅ BSc Biochemistry (91%) - University of Benin Nigeria
Founder and CEO - OneDrug. We are developing smart point-of-care medical device for identifying patients at-risk of adverse drug effects.
Founder and CEO - Mirthomes. We are looking for strategic partners for our real estate portfolios.
🇨🇦🇳🇬
Invited by: Emy
Last 10 Records
if the data has not been changed, no new rows will appear.
| Day | Followers | Gain | % Gain |
|---|---|---|---|
| October 05, 2023 | 501 | +46 | +10.2% |
| January 26, 2023 | 455 | +44 | +10.8% |
| September 29, 2022 | 411 | +39 | +10.5% |
| August 08, 2022 | 372 | +30 | +8.8% |
| July 02, 2022 | 342 | +14 | +4.3% |
| May 26, 2022 | 328 | +13 | +4.2% |
| April 18, 2022 | 315 | +30 | +10.6% |
| March 10, 2022 | 285 | +36 | +14.5% |
| January 12, 2022 | 249 | +23 | +10.2% |
| December 05, 2021 | 226 | +28 | +14.2% |
